Pfizer and Johnson & Johnson said Monday they had given up tests of a new therapy to treat Alzheimer's disease, saying the treatment did not measure up to expectations. The final, phase 3 trial of the intravenous bapineuzumab therapy did not meet targets for effectiveness in aiding cognitive and functional performance of Alzheimer's victims, according to the two drug giants. As a result, they decided to end the program to develop the treatment, they said. "We are obviously very disappointed in the outcomes of this trial. We are also saddened by the lost opportunity to provide a meaningful advance for patients afflicted with mild-to-moderate Alzheimer's disease and their caregivers," said Steven Romano, senior vice president at Pfizer Inc. "Yet these data, and the subgroup and biomarker analyses under way, will further inform our understanding of this complex disease and advance research in this field."
GMT 12:09 2018 Monday ,26 November
Black Friday less wild as more Americans turn to online dealsGMT 15:07 2018 Sunday ,18 November
Refugee host countries discuss UNRWA's financial crisisGMT 17:22 2018 Wednesday ,31 October
Russia climbed to 31st place in Doing Business-2019 ratingGMT 16:53 2018 Wednesday ,17 October
"Putin" We need for collective restoration of Syria's economyGMT 14:02 2018 Friday ,12 October
Govt to announce incentives package for Overseas PakistanisGMT 18:26 2018 Saturday ,06 October
Dubai attracts Dh17.7 billion in foreign direct investmentGMT 09:02 2018 Friday ,21 September
Economy of Georgia demonstrates "strong signs of recovery"GMT 09:03 2018 Wednesday ,24 January
German investor confidence surges in JanuaryMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor